Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Gossamer Bio, Inc.
Gossamer Bio Announces Second Quarter 2024 Financial Results and Provides Business Update
August 12, 2024
From
Gossamer Bio, Inc.
Via
Business Wire
Tickers
GOSS
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
June 07, 2024
From
Gossamer Bio, Inc.
Via
Business Wire
Tickers
GOSS
Gossamer Bio to Provide Updated Seralutinib TORREY Open-Label Extension Data at the American Thoracic Society 2024 International Conference
May 14, 2024
From
Gossamer Bio, Inc.
Via
Business Wire
Tickers
GOSS
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
May 10, 2024
From
Gossamer Bio, Inc.
Via
Business Wire
Tickers
GOSS
Gossamer Bio Announces First Quarter 2024 Financial Results and Provides Business Update
May 07, 2024
From
Gossamer Bio, Inc.
Via
Business Wire
Tickers
GOSS
Gossamer Bio and Chiesi Group Announce Transformative Global Collaboration to Develop and Commercialize Seralutinib in PAH, PH-ILD & Other Indications
May 06, 2024
From
Gossamer Bio, Inc.
Via
Business Wire
Tickers
GOSS
Gossamer Bio Announces Publication of TORREY Phase 2 Results in the Lancet Respiratory Medicine
May 03, 2024
From
Gossamer Bio, Inc.
Via
Business Wire
Tickers
GOSS
Gossamer Bio Announces Appointment of Steven D. Nathan, M.D., and Skye Drynan to its Board of Directors
March 12, 2024
From
Gossamer Bio, Inc.
Via
Business Wire
Tickers
GOSS
Gossamer Bio Announces Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
March 05, 2024
From
Gossamer Bio, Inc.
Via
Business Wire
Tickers
GOSS
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
January 08, 2024
From
Gossamer Bio, Inc.
Via
Business Wire
Tickers
GOSS
Gossamer Bio to Host Webcast to Discuss Latest Seralutinib Open-Label Extension Data on December 18, 2023
December 13, 2023
From
Gossamer Bio, Inc.
Via
Business Wire
Tickers
GOSS
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
December 05, 2023
From
Gossamer Bio, Inc.
Via
Business Wire
Tickers
GOSS
Gossamer Bio Appoints Bob Smith as Chief Commercial Officer
December 05, 2023
From
Gossamer Bio, Inc.
Via
Business Wire
Tickers
GOSS
Gossamer Bio Announces Appointment of John Quisel, J.D., Ph.D., to its Board of Directors
November 29, 2023
From
Gossamer Bio, Inc.
Via
Business Wire
Tickers
GOSS
Gossamer Bio Announces Third Quarter 2023 Financial Results and Provides Business Update
November 09, 2023
From
Gossamer Bio, Inc.
Via
Business Wire
Tickers
GOSS
Gossamer Bio Announces Addition of Rainer Zimmermann, MD, as VP of Medical Affairs
October 03, 2023
From
Gossamer Bio, Inc.
Via
Business Wire
Tickers
GOSS
Gossamer Bio to Present Results of TORREY FRI Sub-Study at the European Respiratory Society International Congress 2023
September 07, 2023
From
Gossamer Bio, Inc.
Via
Business Wire
Tickers
GOSS
Gossamer Bio Announces Second Quarter 2023 Financial Results and Provides Business Update
August 08, 2023
From
Gossamer Bio, Inc.
Via
Business Wire
Tickers
GOSS
Gossamer Bio to Hold Conference Call with PAH Experts to Discuss PROSERA Phase 3 Design and Interim TORREY OLE Results
July 24, 2023
From
Gossamer Bio, Inc.
Via
Business Wire
Tickers
GOSS
Gossamer Bio Announces $212 Million Private Placement Financing
July 20, 2023
From
Gossamer Bio, Inc.
Via
Business Wire
Tickers
GOSS
Gossamer Bio Announces TORREY Data to be Featured at American Thoracic Society 2023 International Conference
May 18, 2023
From
Gossamer Bio, Inc.
Via
Business Wire
Tickers
GOSS
Gossamer Bio Announces First Quarter 2023 Financial Results and Provides Business Update
May 09, 2023
From
Gossamer Bio, Inc.
Via
Business Wire
Tickers
GOSS
Gossamer Bio Announces Fourth Quarter and Full-Year 2022 Financial Results and Provides Business Update
March 17, 2023
From
Gossamer Bio, Inc.
Via
Business Wire
Tickers
GOSS
Gossamer Bio Announces Seralutinib Meets Primary Endpoint in Phase 2 TORREY Study in PAH
December 06, 2022
From
Gossamer Bio, Inc.
Via
Business Wire
Tickers
GOSS
Gossamer Bio Announces Third Quarter 2022 Financial Results and Provides Business Update
November 03, 2022
From
Gossamer Bio, Inc.
Via
Business Wire
Tickers
GOSS
Gossamer Bio Announces Second Quarter 2022 Financial Results and Provides Business Update
August 09, 2022
From
Gossamer Bio, Inc.
Via
Business Wire
Tickers
GOSS
Gossamer Bio Announces $120 Million Private Placement Financing
July 13, 2022
From
Gossamer Bio, Inc.
Via
Business Wire
Tickers
GOSS
Gossamer Bio Announces Publication of Key Preclinical Data in the European Respiratory Journal Highlighting Seralutinib’s Potential for the Treatment of PAH
June 09, 2022
From
Gossamer Bio, Inc.
Via
Business Wire
Tickers
GOSS
Gossamer Bio Announces First Quarter 2022 Financial Results and Provides Business Update
May 10, 2022
From
Gossamer Bio, Inc.
Via
Business Wire
Tickers
GOSS
Gossamer Bio Announces GB004 Topline Results from Phase 2 SHIFT-UC Study in Ulcerative Colitis and Provides Corporate Update
April 25, 2022
From
Gossamer Bio, Inc.
Via
Business Wire
Tickers
GOSS
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.